Loading
Thousands of cancer AI tools have been tested on old data; almost none in a proper trial. Fund the trials, with endpoints that matter to patients.
Systematic reviews find that fewer than a few percent of published oncology AI models have prospective evaluation and vanishingly few have randomised trials with clinical endpoints. Exceptions such as the MASAI mammography screening trial in Sweden show the design is feasible and informative. The proposal is a public and philanthropic fund that pays for pragmatic randomised trials of AI tools in pathology, radiology, screening and decision support, requiring pre-registration, clinical endpoints (cancer detection rate, interval cancers, time to treatment, survival) and open reporting.
Shares AI that is built but not validated or deployed, AI in radiology, Digital pathology & AI.
Shares AI that is built but not validated or deployed, AI in radiology, Digital pathology & AI.
Shares Mammography & tomosynthesis, AI that is built but not validated or deployed, AI in radiology.
Shares Mammography & tomosynthesis, AI that is built but not validated or deployed.